Exicure to Participate in Upcoming Scientific Conferences

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR), a leader in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences in September 2021. These events include TIDES USA 2021, where Exicure will present research on the biodistribution of Spherical Nucleic Acids (SNA) in rats, and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, focusing on SNA targeting FXN for treating Friedreich's Ataxia. Posters will be available on Exicure's website after the events.

Exicure is based in Chicago and Cambridge, developing therapeutics for various genetic disorders.

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc.^® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following scientific conferences during the month of September:

TIDES USA 2021
Poster presentation: "Biodistribution of Spherical Nucleic Acids in the Rat CNS Following ICM and IT Delivery"
September 20 – 30, 2021

17th Annual Meeting of the Oligonucleotide Therapeutics Society
Poster presentation: "Development of Spherical Nucleic Acids Targeting FXN for the Treatment of Friedreich's Ataxia"
September 26 – 29, 2021

Posters will go live at the start of the conference and will be available to conference attendees.

Exicure will add the posters to its website after each conference.

About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005117/en/

Media Contact:

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com

Source: Exicure, Inc.

FAQ

What scientific conferences is Exicure participating in September 2021?

Exicure is participating in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society.

What topics will Exicure present at the conferences?

Exicure will present on the biodistribution of Spherical Nucleic Acids in rats and SNA targeting FXN for Friedreich's Ataxia.

When are the conferences that Exicure is attending?

TIDES USA 2021 is from September 20 to 30, 2021, and the Oligonucleotide Therapeutics Society meeting is from September 26 to 29, 2021.

Where can I find Exicure's conference posters?

Exicure's posters will be available on their website after each conference.

What is the focus of Exicure's therapeutic development?

Exicure is focusing on therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders.